| A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (NCT05371613) | Denali Therapeutics Inc. | 2022-07-21 |
| Registry of Patients Diagnosed With Lysosomal Storage Diseases (NCT05619900) | University of California, San Francisco | 2022-05-31 |
| MPS II Immunophenotyping (NCT04976231) | Duke University | 2022-04-01 |
| A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT) (NCT04573023) | JCR Pharmaceuticals Co., Ltd. | 2022-02-14 |
| ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program (NCT05368038) | Albert Einstein College of Medicine | 2021-05-10 |
| Long-term Follow-Up for RGX-121 (NCT04597385) | REGENXBIO Inc. | 2021-03-14 |
| Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX (NCT04628871) | Sangamo Therapeutics | 2020-11-03 |
| A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome (NCT04251026) | Denali Therapeutics Inc. | 2020-07-16 |
| A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome (NCT04007536) | Denali Therapeutics Inc. | 2019-10-23 |
| An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II (NCT04348136) | JCR Pharmaceuticals Co., Ltd. | 2019-09-01 |
| An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II (NCT03708965) | JCR Pharmaceuticals Co., Ltd. | 2019-01-01 |
| Biomarkers for Hunter Syndrome (NCT01330277) | CENTOGENE GmbH Rostock | 2018-08-20 |
| A Study of JR-141 in Patients With Mucopolysaccharidosis II (NCT03568175) | JCR Pharmaceuticals Co., Ltd. | 2018-08-01 |
| MPS (RaDiCo Cohort) (RaDiCo-MPS) (NCT06036693) | Institut National de la Santé Et de la Recherche Médicale, France | 2017-12-20 |
| Mucopolysaccharidosis Type II Natural History (NCT03529786) | REGENXBIO Inc. | 2017-09-27 |
| Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI (NCT03153319) | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2017-06-05 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (NCT03041324) | Sangamo Therapeutics | 2017-05-11 |
| A Study of JR-141 in Patients With Mucopolysaccharidosis Type II (NCT03128593) | JCR Pharmaceuticals Co., Ltd. | 2017-03-30 |
| Study of Idursulfase-beta (GC1111) in Hunter Syndrome (NCT02663024) | Green Cross Corporation | 2016-12-01 |
| Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome (NCT02262338) | ArmaGen, Inc | 2015-04-01 |
| A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723 (NCT01602601) | GlaxoSmithKline | 2012-04-09 |
| Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics (NCT01675674) | National MPS Society | 2011-09-01 |
| To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients (NCT01301898) | Green Cross Corporation | 2010-05-01 |
| Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy (NCT00607386) | Shire | 2007-12-31 |
| Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) (NCT00069641) | Shire | 2003-09-18 |
| Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) (NCT00004454) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1996-10-01 |